Latest news with #JimiOlaghere
Yahoo
8 hours ago
- Business
- Yahoo
PODD Drug Delivery Conference Announces 2025 Keynotes
The Conference Forum announces the 15th annual PODD Drug Delivery Conference's 2025 keynotes NEW YORK, June 18, 2025 /PRNewswire/ -- Today, PODD: Partnership Opportunities in Drug Delivery conference announced the keynotes for its 15th annual conference which takes place on October 27-28 at the Westin Copley Place in Boston, MA. "In presenting a strategic-level program for R&D scientists and business development professionals, the PODD Conference is committed to securing keynotes who demonstrate excellence in science," said Andrew Goldstein, Senior Conference Producer for the PODD Conference. The PODD 2025 keynotes include: MIT's Dr Robert Langer, a pioneer in the research and development of drug delivery technology, will return as the Annual Keynote to discuss the state of innovation in the drug delivery industry. Dr Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor who drove the development of GLP-1 drugs for obesity will present on the liraglutide and semaglutide story, her approach to scientific development and where drug delivery intersects with her R&D work. Patient Keynote Jimi Olaghere will share his journey as a patient with sickle cell disease before and after receiving CASGEVY, a CRISPR-based therapy, and his mission to make these therapies more accessible for patients globally. Dr Mansoor Amiji, University Distinguished Professor, Northwestern University, will join the PODD Conference as the Endogenous Delivery Zeitgeist. Dr Amiji will present on endogenous targeted delivery strategies to overcome biological barriers and improve efficacy and safety. The PODD speaking faculty includes over 100 executives from both the drug development and delivery industries with over 125 session choices including a full afternoon of drug delivery presentations from established to start-up companies. To learn more about the event, visit About the PODD: Partnership Opportunities in Drug Delivery ConferencePharma, biotech and the drug delivery industries gather annually at PODD to assess delivery needs, latest trends and information on deals, and learn about a wide range of innovative drug delivery technologies that could improve the delivery of various types of drugs. This can include proteins, peptides, oligonucleotides, biologics, small molecules and more. PODD provides business development opportunities through organized networking and a partnering tool for new, emerging and established collaborations. About the Conference ForumThe Conference Forum is a life science industry research firm that develops conferences, podcasts, newsletters and webinars primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. They are committed to creating the best content, promoting the exchange of ideas and solutions among peers, and providing high-quality networking. Learn more about the Conference Forum at For media inquiries, contact:Bre Bugbee-Barrettbre@ View original content: SOURCE Partnership Opportunities in Drug Delivery (PODD)
Yahoo
08-05-2025
- Business
- Yahoo
DIA 2025 Global Annual Meeting Spotlights the Power of Collaboration Amid Shifting Regulatory Priorities
Meeting will deliver real-time insight, cross-border coordination, and actionable solutions in the face of uncertainty and change WASHINGTON, May 08, 2025--(BUSINESS WIRE)--DIA, a global non-profit organization of life sciences professionals, will unite thousands of stakeholders to address the future of international regulatory cooperation during the DIA 2025 Global Annual Meeting from June 15-19 in Washington. As policy shifts and regulatory relationships grow more uncertain, DIA 2025 gives the global life sciences community a place to confront these changes as they're unfolding. Recent changes in international health policy have underscored the need for collective action and raised fresh concerns about the fragmentation of global health efforts. At the same time, encouraging steps toward regulatory convergence continue emerging, including the establishment of the African Medicines Agency and Japan aligning its post-marketing surveillance practices with U.S. and European standards. The need for coordinated action has never been greater. DIA 2025 offers the scientific community an opportunity to share information, align on healthcare goals, and tackle the industry's most pressing challenges head-on. With more than 200 sessions across 12 content tracks, the event welcomes regulators, researchers, advocates, and innovators from nearly 50 countries to confront how shifting priorities and policy changes are reshaping innovation, access, and global collaboration. "Scientific progress relies on transparency, access, and evidence," said Marwan Fathallah, DIA's President and Global Chief Executive. "At a time of change, we must not lose sight of our mission of advancing science to improve patient lives. DIA 2025 will be where the global community comes together to solve problems, share knowledge, strengthen collaboration, and drive better outcomes for people everywhere." As a global life sciences association committed to supporting professionals throughout their careers, DIA is offering one year of DIA membership and complimentary registration to the U.S. Food and Drug Administration, National Institutes of Health, and Department of Health and Human Services professionals who were recently laid off. Impacted individuals should complete this form to process their request. The new "Career Connections" initiative will provide networking opportunities and foster connections with employers during their career transitions. An FDA Appreciation Event, open to all registrants, will honor the contributions of professionals past and present who make the industry possible. Keynote speakers Jimi Olaghere, a sickle cell disease advocate whose experience receiving CRISPR-based gene therapy represents a powerful milestone in patient-led innovation, and Dr. Doug Melton, a distinguished research fellow at Vertex Pharmaceuticals who is renowned for his stem cell research, will address the impact of scientific progress and aligning regulatory systems with innovation. Regulatory town halls will again be cornerstones of the conference program. Representatives from several global health authorities, including U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), will share updates on their initiatives and discuss harmonization strategies. As always, DIAmond sessions will tackle the life sciences' most pressing challenges. One will focus on how Identification of Medicinal Products (IDMP) standards can address global healthcare challenges. Another will explore rare disease treatment development, including market access and pricing after accelerated approval. A third will center on the importance of including women in clinical trials and redesigning research policies to reflect that priority. Ethics and patient-centered approaches will be woven throughout the program. Additional topics include real-world data (RWD) collection, using AI in pharmacovigilance and safety monitoring, the latest on ICH E6(R3) implementation, recent changes to the Declaration of Helsinki, and regulatory strategies tailored to emerging markets. Government attendees can now register for DIA 2025 at the reduced rate of $665. Late rates for industry professionals take effect after May 15, so early registration is encouraged. Click here for the event program. Media members can request credentials by emailing diaglobal@ About DIA DIA is a leading global non-profit life science membership association that drives collaboration in drug, device, and diagnostics development in pursuit of a healthier world. Founded in 1964 with headquarters in Washington, D.C., and offices in Europe and Asia, DIA provides unparalleled networking opportunities, educational resources, scientific research publications, and professional development programs to members in more than 80 countries. Learn more at and connect with DIA on LinkedIn, Facebook, X (Twitter), and Instagram. View source version on Contacts Media Contacts Katie KennedyGregory FCAdiaglobal@ 610-731-1045 Kali GillGregory FCAdiaglobal@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
08-05-2025
- Business
- Business Wire
DIA 2025 Global Annual Meeting Spotlights the Power of Collaboration Amid Shifting Regulatory Priorities
WASHINGTON--(BUSINESS WIRE)-- DIA, a global non-profit organization of life sciences professionals, will unite thousands of stakeholders to address the future of international regulatory cooperation during the DIA 2025 Global Annual Meeting from June 15-19 in Washington. As policy shifts and regulatory relationships grow more uncertain, DIA 2025 gives the global life sciences community a place to confront these changes as they're unfolding. Recent changes in international health policy have underscored the need for collective action and raised fresh concerns about the fragmentation of global health efforts. At the same time, encouraging steps toward regulatory convergence continue emerging, including the establishment of the African Medicines Agency and Japan aligning its post-marketing surveillance practices with U.S. and European standards. The need for coordinated action has never been greater. DIA 2025 offers the scientific community an opportunity to share information, align on healthcare goals, and tackle the industry's most pressing challenges head-on. With more than 200 sessions across 12 content tracks, the event welcomes regulators, researchers, advocates, and innovators from nearly 50 countries to confront how shifting priorities and policy changes are reshaping innovation, access, and global collaboration. "Scientific progress relies on transparency, access, and evidence," said Marwan Fathallah, DIA's President and Global Chief Executive. "At a time of change, we must not lose sight of our mission of advancing science to improve patient lives. DIA 2025 will be where the global community comes together to solve problems, share knowledge, strengthen collaboration, and drive better outcomes for people everywhere." As a global life sciences association committed to supporting professionals throughout their careers, DIA is offering one year of DIA membership and complimentary registration to the U.S. Food and Drug Administration, National Institutes of Health, and Department of Health and Human Services professionals who were recently laid off. Impacted individuals should complete this form to process their request. The new "Career Connections" initiative will provide networking opportunities and foster connections with employers during their career transitions. An FDA Appreciation Event, open to all registrants, will honor the contributions of professionals past and present who make the industry possible. Keynote speakers Jimi Olaghere, a sickle cell disease advocate whose experience receiving CRISPR-based gene therapy represents a powerful milestone in patient-led innovation, and Dr. Doug Melton, a distinguished research fellow at Vertex Pharmaceuticals who is renowned for his stem cell research, will address the impact of scientific progress and aligning regulatory systems with innovation. Regulatory town halls will again be cornerstones of the conference program. Representatives from several global health authorities, including U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), will share updates on their initiatives and discuss harmonization strategies. As always, DIAmond sessions will tackle the life sciences' most pressing challenges. One will focus on how Identification of Medicinal Products (IDMP) standards can address global healthcare challenges. Another will explore rare disease treatment development, including market access and pricing after accelerated approval. A third will center on the importance of including women in clinical trials and redesigning research policies to reflect that priority. Ethics and patient-centered approaches will be woven throughout the program. Additional topics include real-world data (RWD) collection, using AI in pharmacovigilance and safety monitoring, the latest on ICH E6(R3) implementation, recent changes to the Declaration of Helsinki, and regulatory strategies tailored to emerging markets. Government attendees can now register for DIA 2025 at the reduced rate of $665. Late rates for industry professionals take effect after May 15, so early registration is encouraged. Click here for the event program. Media members can request credentials by emailing diaglobal@ About DIA DIA is a leading global non-profit life science membership association that drives collaboration in drug, device, and diagnostics development in pursuit of a healthier world. Founded in 1964 with headquarters in Washington, D.C., and offices in Europe and Asia, DIA provides unparalleled networking opportunities, educational resources, scientific research publications, and professional development programs to members in more than 80 countries. Learn more at and connect with DIA on LinkedIn, Facebook, X (Twitter), and Instagram.
